

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	The Hydration Pharmaceuticals Company Limited
ABN	83 620 385 677

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Nicholas Berry
Date of appointment	25 May 2024

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

+ See chapter 19 for defined terms.

Appendix 3X
Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
<p>Note: Provide details of the circumstances giving rise to the relevant interest.</p> <p>Pure Asset Management Pty Ltd as trustee for The Pure Income and Growth Fund*</p> <p>*Mr Berry is deemed to have the same relevant interests in securities that Pure Asset Management as trustee for The Pure Income and Growth Fund has by virtue of section 608(3)(a) of the Corporations Act.</p>	<p>60,952,123 fully paid ordinary shares</p> <p>52,442,532 unlisted warrants</p> <p>6,686,844 unlisted options @ \$0.07 EXP 31/12/25</p>

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
	<p>The Company has entered into the following agreements with Pure Asset Management Pty Ltd as trustee for The Pure Income and Growth Fund (Pure):</p> <ul style="list-style-type: none"> • A\$12m two-tranche secured loan facility dated 17 October 2022 (Original Facility) and Warrant Deed; and • a variation to the Original Facility pursuant to which Pure may extend three additional tranches of funding to the Company dated 27 March 2024 (Amended Facility) and Second Warrant Deed. <p>Under the Original Facility and Warrant Deed, Pure is entitled to be issued a number of Tranche B Warrants on draw down of the Second Loan. Please refer to ASX announcement dated 17 October 2022 for further details.</p> <p>Under the Amended Facility and Second Warrant Deed, Pure is entitled to be issued a number of Tranche D and Tranche E warrants to be calculated at the time the Fourth and Fifth Loans are respectively drawn down. Please refer to ASX announcement dated 27 March 2024 for further details.</p>

+ See chapter 19 for defined terms.

Nature of interest	Mr Berry is deemed to have the same relevant interests in securities that Pure Asset Management as trustee for The Pure Income and Growth Fund has by virtue of section 608(3)(a) of the Corporations Act.
Name of registered holder (if issued securities)	J P Morgan Nominees Pty Ltd
No. and class of securities to which interest relates	<p>The number of Tranche B warrants to be issued will be calculated by dividing the Second Loan Amount by an amount equal to the Tranche B Exercise Price, which is calculated at the time of utilisation of the Second Loan.</p> <p>The number of Tranche D warrants to be issued will be calculated by dividing the Fourth Loan Amount by an amount equal to the Tranche D Exercise Price, which is calculated at the time of utilisation of the Fourth Loan.</p> <p>The number of Tranche E warrants to be issued will be calculated by dividing the Fifth Loan Amount by an amount equal to the Tranche E Exercise Price, which is calculated at the time of utilisation of the Fifth Loan.</p>

+ See chapter 19 for defined terms.